UNITED STATES:Congress will bolster pharma regulation
You must be signed in to read this analysis
In this article
- Vioxx (rofecoxib)
- Bextra (valdecoxib)
- Risk-benefit analysis
- Reform agenda
- Post-marketing safety
- Surveillance
- Managing risks
- Reauthorisations
- Approval errors
- Incentive problems
- Broader FDA challenges
- Behavioural
- Legal
- Structural
What is this?
This article is from the Oxford Analytica Daily Brief, which analyses geopolitical, economic, social, business and industrial developments on a global and regional basis, providing clients with timely, authoritative analysis every business day of the year. Find out more about the Oxford Analytica Daily Brief, or request a trial.